Simplify Logo

Full-Time

Executive Director/Vice President

Program Leadership

Confirmed live in the last 24 hours

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops gene editing technology for genetic medicine

Healthcare
Biotechnology

Expert

Cambridge, MA, USA

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • An advanced degree in Life Sciences (PhD, MD, M.Sc., Pharm.D., or equivalent)
  • 15+ years in the biopharmaceutical industry in leadership positions working on programs from preclinical development to commercialization
  • Proven and respected leadership of cross-functional development teams in a matrixed environment, with an exceptional track record of delivering on business objectives and activity/milestones leading to filing and launching
  • An in-depth understanding of how CMC, Nonclinical, Clinical/Medical, Regulatory and Quality disciplines need to partner to expedite development
  • Strong know-how to quickly develop and maintain broad program knowledge (relevant platform, key data and precedents, patient population, market and policy environment, competitive development and global payer landscape, etc.)
  • Proven ability to establish and maintain credible and trust-based relationships with external stakeholders (e.g., KOLs, patient advocacy groups, etc.)
Responsibilities
  • Establishing vision and strategy to lead two Program teams developing genome editing therapies for rare diseases, from early development through to registration
  • Providing strategic leadership and development acumen as part of the company's Leadership Team
  • Promoting collaborative and socially intelligent team environments with effective communication
  • Managing target product profiles, ensuring alignment across the enterprise
  • Being accountable for the execution of integrated development plans to agreed scope, timelines, resources, & budget- collaborating and partnering with the appropriate leaders across the enterprise
  • Leading communication on program development strategy at governance meetings, and driving optimization of programs decision-making, using Tessera’s internal decision-making framework
  • Partnering with key internal stakeholders and Program Managers to ensure timelines, processes, plans and data are in place to enable investment decisions and prioritization across the enterprise portfolio
  • Fostering a development culture of collaboration and innovation, focused on scientific excellence, data-driven arguments, and efficiency
  • Maintaining clear internal communication on program status, priorities, risks, and needs as primary advocate for the programs (including with senior leadership)
  • Monitoring and guiding the program budgets in collaboration with PM and Finance

Tessera Therapeutics focuses on genetic medicine, utilizing a technology called Gene Writing to make precise changes to the human genome. This technology allows for permanent alterations to genetic material in any cell, which can potentially cure diseases at their source. The Gene Writing platform can perform both small and large genetic modifications, making it applicable to a wide range of genetic disorders. Tessera Therapeutics collaborates with research institutions, pharmaceutical companies, and healthcare providers to develop new treatments for genetic diseases. Unlike many competitors, Tessera's approach emphasizes the ability to address previously untreatable conditions through its proprietary technology. The company's goal is to advance the development of Gene Writing to ultimately cure diseases by rewriting the genetic code.

Company Stage

Series C

Total Funding

$581.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-10%

1 year growth

-6%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tessera's innovative Gene Writing technology has the potential to cure previously untreatable genetic conditions, offering a transformative impact on healthcare.
  • The company's strategic partnerships and licensing agreements with major pharmaceutical firms and research institutions can drive significant revenue growth and market penetration.
  • Recent leadership appointments, including a new General Counsel and Chief Regulatory Officer, bring extensive industry experience that can guide the company through regulatory and commercial milestones.

What critics are saying

  • The highly competitive biotechnology sector requires continuous innovation to maintain Tessera's market position.
  • Regulatory hurdles and the complexity of clinical trials for genetic therapies could delay product development and commercialization.

What makes Tessera Therapeutics unique

  • Tessera Therapeutics' Gene Writing technology offers a unique capability to make precise and permanent genetic alterations, setting it apart from traditional gene editing methods.
  • The company's focus on a wide range of genetic disorders, from phenylketonuria to sickle cell disease, showcases the versatility and broad applicability of its platform.
  • Securing $300 million in Series C financing highlights strong investor confidence and provides substantial resources for advancing their groundbreaking technology.